How UTHR’s Remodulin, Adcirca, and Unituxin Performed in 3Q17

Remodulin revenue trends

In 3Q17, United Therapeutics’ (UTHR) Remodulin reported revenues of $187.3 million, which reflected ~23% growth on a year-over-year (or YoY) basis and ~19% growth on a quarter-over-quarter basis. Remodulin reported revenues of $490.8 million in the first nine months of 2017 compared to $451.1 million in the corresponding period in 2016, a 9% increase on a YoY basis.

During 3Q17, a one-time purchase of Remodulin of around $47.4 million by an international distributor primarily accounted for the revenue growth of Remodulin. The increasing number of patients using Remodulin also pushed the drug’s sales growth. To know more about Remodulin, read How Is United Therapeutics’ Remodulin Positioned in 2017?

How UTHR’s Remodulin, Adcirca, and Unituxin Performed in 3Q17

Adcirca revenue trends

In 3Q17, Adcirca reported revenues of $99.8 million, which reflected ~4% growth on a YoY basis and a 17% decline on a quarter-over-quarter basis. Adcirca reported revenues of $280.5 million in the first nine months of 2017 compared to $311.0 million in the corresponding period of 2016, reflecting a 10% decline on a YoY basis. Adcirca is used for the treatment of pulmonary arterial hypertension to improve exercise ability.

Unituxin revenue trends

In 3Q17, Unituxin reported revenues of $17 million, which reflected a ~2% decline on a YoY basis and 6% growth on a quarter-over-quarter basis. Unituxin reported revenues of $51.1 million in the first nine months of 2017 compared to $49.3 million in the corresponding period of 2016, reflecting 4% growth on a YoY basis.

Unituxin (dinutuximab) is used for the treatment of children with neuroblastoma who achieved a partial response to previous multi-agent, multimodality therapy.

United Therapeutics’ peers in the PAH drug market include GlaxoSmithKline (GSK), Teva Pharmaceuticals (TEVA), Bayer (BAYZF), and Gilead Sciences. In 3Q17, GlaxoSmithKline, Teva Pharmaceuticals, Bayer, and Gilead Sciences reported revenues of 7.8 billion British pounds, $5.6 billion, 8.0 billion euros, and $6.5 billion, respectively.

The revenue growth of United Therapeutics’ PAH portfolio could boost the SPDR S&P Mid-Cap 400 ETF (MDY). United Therapeutics makes up about ~0.30% of MDY’s total portfolio holdings.